Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.

Misako Nagasaka, MD, PhD, explains how subcutaneous amivantamab’s shorter administration time benefits patients and infusion centers.

Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.

Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma.

Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.

Adult T-cell lymphoma and leukemia may warrant upfront allogeneic transplant, according to Mary Jo Lechowicz, MD.

The OMNI-EGFR inhibitor BH-30643 produced a 45% objective response rate among patients with EGFR C797S–positive disease in the phase 1/2 SOLARA trial.

New data on antibody drug conjugates and extended survival follow-ups may inform clinical decision-making surrounding non–small cell lung cancer.